Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity?
| Autor: | Rita Lin, Linda Frost, Adamandia D. Kriketos, Geoffrey C. Farrell, Christopher Liddle, Shivakumar Chitturi, Jacob George, Dev Samarasinghe |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Hepatology business.industry Insulin medicine.medical_treatment Leptin digestive oral and skin physiology Fatty liver Type 2 diabetes medicine.disease Insulin resistance Endocrinology Lipotoxicity Fibrosis Internal medicine medicine Steatosis business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Hepatology. 36:403-409 |
| ISSN: | 0270-9139 |
| DOI: | 10.1053/jhep.2002.34738 |
| Popis: | Nonalcoholic steatohepatitis (NASH) is a disorder characterized by hepatic steatosis, inflammation, and fibrosis. Leptin is an adipocyte-derived antiobesity hormone that in rodents prevents "lipotoxicity" by limiting triglyceride accumulation and also regulates matrix deposition (fibrosis) during wound healing. We therefore determined serum leptin levels in patients with NASH to determine whether relationships existed between leptin levels and severity of hepatic steatosis or fibrosis. We used a radioimmunoassay to determine serum [total] leptin concentrations in 27 men and 20 women with NASH and 47 controls matched for gender and body mass index (BMI; and partly for age). Serum leptin values were correlated with hepatic steatosis, fibrosis, and inflammation (each categorized semiquantitatively on liver histology), and with anthropometric indices, serum lipids, glucose, insulin, c-peptide, and alanine aminotransferase (ALT) levels. Compared with the controls, mean serum leptin levels were raised in both men and women with NASH (men 14 +/- 11 ng/mL vs. 7.2 +/- 4.1 ng/mL, P =.003; women 35 +/- 16 ng/mL vs. 15 +/- 8.2 ng/mL, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text